201 related articles for article (PubMed ID: 15240546)
1. Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.
Boghaert ER; Sridharan L; Armellino DC; Khandke KM; DiJoseph JF; Kunz A; Dougher MM; Jiang F; Kalyandrug LB; Hamann PR; Frost P; Damle NK
Clin Cancer Res; 2004 Jul; 10(13):4538-49. PubMed ID: 15240546
[TBL] [Abstract][Full Text] [Related]
2. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
[TBL] [Abstract][Full Text] [Related]
3. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
[TBL] [Abstract][Full Text] [Related]
5. Structural convergence of antibody binding of carbohydrate determinants in Lewis Y tumor antigens.
Ramsland PA; Farrugia W; Bradford TM; Mark Hogarth P; Scott AM
J Mol Biol; 2004 Jul; 340(4):809-18. PubMed ID: 15223322
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1.
Knoll K; Wrasidlo W; Scherberich JE; Gaedicke G; Fischer P
Cancer Res; 2000 Nov; 60(21):6089-94. PubMed ID: 11085532
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Clin Cancer Res; 2000 Sep; 6(9):3621-8. PubMed ID: 10999754
[TBL] [Abstract][Full Text] [Related]
8. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Shochat D; Mountain A
Bioconjug Chem; 2005; 16(2):354-60. PubMed ID: 15769089
[TBL] [Abstract][Full Text] [Related]
9. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.
DiJoseph JF; Armellino DC; Boghaert ER; Khandke K; Dougher MM; Sridharan L; Kunz A; Hamann PR; Gorovits B; Udata C; Moran JK; Popplewell AG; Stephens S; Frost P; Damle NK
Blood; 2004 Mar; 103(5):1807-14. PubMed ID: 14615373
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma.
Henry CJ; Buss MS; Hellström I; Hellström KE; Brewer WG; Bryan JN; Siegall CB
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):751-5. PubMed ID: 15701865
[TBL] [Abstract][Full Text] [Related]
11. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
12. Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels.
Krug LM; Milton DT; Jungbluth AA; Chen LC; Quaia E; Pandit-Taskar N; Nagel A; Jones J; Kris MG; Finn R; Smith-Jones P; Scott AM; Old L; Divgi C
J Thorac Oncol; 2007 Oct; 2(10):947-52. PubMed ID: 17909358
[TBL] [Abstract][Full Text] [Related]
13. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer.
Zhou J; Chen J; Mokotoff M; Zhong R; Shultz LD; Ball ED
Clin Cancer Res; 2003 Oct; 9(13):4953-60. PubMed ID: 14581370
[TBL] [Abstract][Full Text] [Related]
14. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
Griffiths GL; Mattes MJ; Stein R; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2003 Dec; 9(17):6567-71. PubMed ID: 14695162
[TBL] [Abstract][Full Text] [Related]
15. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Cancer Res; 2000 Sep; 60(17):4804-11. PubMed ID: 10987290
[TBL] [Abstract][Full Text] [Related]
16. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
[TBL] [Abstract][Full Text] [Related]
18. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.
Scott AM; Tebbutt N; Lee FT; Cavicchiolo T; Liu Z; Gill S; Poon AM; Hopkins W; Smyth FE; Murone C; MacGregor D; Papenfuss AT; Chappell B; Saunder TH; Brechbiel MW; Davis ID; Murphy R; Chong G; Hoffman EW; Old LJ
Clin Cancer Res; 2007 Jun; 13(11):3286-92. PubMed ID: 17545534
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
[TBL] [Abstract][Full Text] [Related]
20. Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses.
Liu Z; Panousis C; Smyth FE; Murphy R; Wirth V; Cartwright G; Johns TG; Scott AM
Hybrid Hybridomics; 2003 Aug; 22(4):219-28. PubMed ID: 14511567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]